- Home
- IGIC vs XNCR Comparison
IGIC vs XNCR Comparison
Compare IGIC & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IGIC | XNCR |
|---|---|---|
| Founded | 2001 | 1997 |
| Country | Jordan | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 992.2M | 881.9M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | IGIC | XNCR |
|---|---|---|
| Price | $26.27 | $12.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $28.00 | $22.33 |
| AVG Volume (30 Days) | 59.0K | ★ 785.2K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $0.13 | N/A |
| Revenue Next Year | $2.54 | $4.80 |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $20.82 | $6.92 |
| 52 Week High | $26.40 | $18.69 |
Technical Indicators
Market Signals| Indicator | IGIC | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 69.97 | 54.65 |
| Support Level | $23.20 | $12.29 |
| Resistance Level | N/A | $12.87 |
| Average True Range (ATR) | 0.67 | 0.80 |
| MACD | 0.30 | 0.04 |
| Stochastic Oscillator | 99.28 | 70.51 |
Price Performance
Historical ComparisonAbout IGIC International General Insurance Holdings Ltd.
International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.